Scandinavian ChemoTech (CMOTEC) Q1 2026 earnings summary

Executive summary

• Achieved strongest first quarter in company history with net sales of 2,798 KSEK, up from 2,472 KSEK year-over-year.

• Operational improvements and disciplined cost control led to reduced net loss of -1,573 KSEK compared to -3,322 KSEK last year.

• Surpassed 50 installed systems globally, reflecting increased commercial reliability and scalability.

• Continued focus on Animal Care, with all Q1 sales from this segment and growing adoption of TSE technology.

Financial highlights

• Net sales rose to 2,798 KSEK from 2,472 KSEK year-over-year.

• Net loss after financial items improved to -1,573 KSEK from -3,322 KSEK year-over-year.

• EBITDA for Animal Care was 364 KSEK, up from 66 KSEK year-over-year.

• Cash flow from operating activities was -1,143 KSEK, slightly better than -1,239 KSEK last year.

• Cash and cash equivalents at quarter-end were 1,455 KSEK, up from 1,017 KSEK year-over-year.

Outlook and guidance

• Continued prioritization of disciplined execution, operational efficiency, and sustainable growth.

• Investments in sales organization and staff training planned for North America and Central Europe.

• Additional funding required to maintain operations over the next twelve months; management actively seeking financing.